Radiation Oncology Institute launched with $5 million ASTRO grant

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 9
Volume 17
Issue 9

FAIRFAX, Virginia-The American Society for Therapeutic Radiology and Oncology (ASTRO) has invested $5 million in the newly created Radiation Oncology Institute (ROI). The goal of ROI is to support research and education in radiation therapy.

FAIRFAX, Virginia-The American Society for Therapeutic Radiology and Oncology (ASTRO) has invested $5 million in the newly created Radiation Oncology Institute (ROI). The goal of ROI is to support research and education in radiation therapy.

 

Theodore S. Lawrence, MD, PhD, from the University of Michigan in Ann Arbor and Colleen A. Lawton, MD, from the Medical College of Wisconsin in Milwaukee will lead the endowment campaign. Their goal is to raise $10 million in capital to build the infrastructure of the new ROI, according to ASTRO.

 

Once ROI is functional, it will serve as the chief philanthropic partner to ASTRO. Possible ROI programs include supporting research studies or impact analyses of new and existing treatment options; conducting outcomes studies on the efficacy and cost/ benefit of radiation therapy; and publishing radiation oncology-related trend data. ROI also will build a database of workforce and practice structures.

 

From ASTRO’s $5 million investment, $1 million will be used for an endowment and $1 million for initial seed funding.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.